Bone Metastases

Oncology
6
Pipeline Programs
6
Companies
6
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

On Market (3)

Approved therapies currently available

U
BILDYOSApproved
denosumab
Unknown Company
RANK Ligand Inhibitor [EPC]injection2025
U
BILPREVDAApproved
denosumab
Unknown Company
RANK Ligand Inhibitor [EPC]injection2025
U
ZOLEDRONIC ACIDApproved
zoledronic acid
Unknown Company
intravenous2017

Competitive Landscape

5 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
1 program
1
DenosumabPhase 3Monoclonal Antibody
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1206Phase 31 trial
Active Trials
NCT04550949UnknownEst. Jun 2022
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
zoledronic acidPhase 33 trials
Active Trials
NCT01967160Completed2,560Est. Aug 2019
NCT01099436Completed250Est. Sep 2013
NCT00321620Completed1,904Est. Feb 2012
Quantum Surgical
Quantum SurgicalFrance - Montpellier
1 program
CT-guided bone percutaneous procedureN/A1 trial
Active Trials
NCT06376682Completed34Est. Jan 2025
Accuray
AccurayMADISON, WI
1 program
radiosurgical hypophysectomyN/A1 trial
Active Trials
NCT03377517Terminated5Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalQL1206
Amgenzoledronic acid
Amgenzoledronic acid
Quantum SurgicalCT-guided bone percutaneous procedure
Accurayradiosurgical hypophysectomy
Amgenzoledronic acid

Clinical Trials (6)

Total enrollment: 4,753 patients across 6 trials

NCT04550949Qilu PharmaceuticalQL1206

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Start: Apr 2019Est. completion: Jun 2022
Phase 3Unknown
NCT01099436Amgenzoledronic acid

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients

Start: Apr 2010Est. completion: Sep 2013250 patients
Phase 3Completed
NCT00321620Amgenzoledronic acid

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

Start: Apr 2006Est. completion: Feb 20121,904 patients
Phase 3Completed
NCT06376682Quantum SurgicalCT-guided bone percutaneous procedure

EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy

Start: Sep 2024Est. completion: Jan 202534 patients
N/ACompleted
NCT03377517Accurayradiosurgical hypophysectomy

Radiosurgical Hypophysectomy for Bone Metasteses Pain

Start: May 2018Est. completion: May 20245 patients
N/ATerminated
NCT01967160Amgenzoledronic acid

Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid

Start: Jan 2012Est. completion: Aug 20192,560 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3h ago

Office Administrator

SystImmune
3h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)